

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

**Claims 1.–52. (Cancelled)**

**Claim 53. (Currently Amended)** ~~A method for diagnosing diseases which are associated with disturbed glucose transport wherein at least one substance for~~ obesity comprising detecting the expression and/or function of activated ~~and/or inactive Sgk, in particular Sgk1 with an antibody directed thereto~~ and/or Sgk3, and/or PKB, and/or Nedd, in particular Nedd4-2, is used.

**Claim 54. (Cancelled)**

**Claim 55. (Currently Amended)** ~~The method of claim 53, characterized in that use is made of antibodies which are~~ wherein the antibody is directed against phosphorylated and/or unphosphorylated sequences in ~~Sgk, in particular Sgk1 and/or Sgk3, and/or PKB, and/or Nedd, in particular Nedd4-2.~~

**Claim 56. (Currently Amended)** ~~The method of claim 55, characterized in that use is made of antibodies which are~~ wherein the antibody is directed against at least one phosphorylated and/or unphosphorylated ~~kinase consensus sequence, in particular an Sgk1 consensus sequence, in a Nedd protein, in particular in the Nedd4-2 protein.~~

**Claim 57. (Cancelled)**

**Claim 58. (Cancelled)**

**Claim 59. (Currently Amended)** ~~The method of claim 53, characterized in that at least one mutation, in particular an activating mutation, is detected in sgk, in particular in sgk1 and/or sgk3, and/or a gene for PKB, in DNA, RNA and/or an Sgk protein and/or PKB protein from a biological sample, in particular a sample from a patient.~~

**Claim 60. (Currently Amended)** The method of claim 59, ~~characterized in that~~ wherein the mutation is S422DSgk1 ~~and/or T308D,S473DPKB.~~

**Claim 61. (Cancelled)**

**Claim 62. (Currently Amended)** A method for diagnosing predispositions to obesity comprising detecting at least one polymorphism which is E8CC/CT;I6CC in sgk1, ~~characterized in that at least one polymorphism is detected in sgk, in particular sgk1 and/or sgk3, a gene for PKB, nedd, in particular nedd4-2, and/or sglt, in particular sglt1.~~

**Claim 63. (Cancelled)**

**Claim 64. (Cancelled)**

**Claim 65. (Withdrawn)** A method for exerting an effect on glucose transport, in particular intestinal and/or renal glucose transport in which at least one active compound is used.

**Claim 66. (Withdrawn)** The method of claim 65, characterized in that the active compound exerts an effect on at least one Sgk, in particular Sgk1 and/or Sgk3, and/or PKB, and/or an effect on at least one Nedd, in particular Nedd4-2.

**Claim 67. (Withdrawn)** The method of claim 65, characterized in that the active compound is directed against an Sgk, in particular Sgk1 and/or Sgk3, and/or PKB and/or a Nedd, in particular Nedd4-2.

**Claim 68. (Withdrawn)** The method of claim 65, characterized in that the active compound is directed against activators, inhibitors, regulators and/or biological precursors of an Sgk, in particular of Sgk1 and/or Sgk3, and/or PKB and/or a Nedd, in particular Nedd4-2.

**Claim 69. (Withdrawn)** The method of claim 65, characterized in that the active compound is a polynucleotide which preferably encodes a peptide, in particular a polypeptide.

**Claim 70. (Withdrawn)** The method of claim 65, characterized in that the active compound

is a peptide, preferably a polypeptide.

**Claim 71. (Withdrawn)** The method of claim 70, characterized in that the peptide exerts an effect on the expression and/or function of an Sgk, in particular Sgk1 and/or Sgk3, and/or PKB and/or a Nedd, in particular Nedd4-2.

**Claim 72. (Withdrawn)** The method of claim 65, characterized in that the active compound is a “small molecular compound”, preferably a “small molecular compound” having a molecular weight (MW) of < 1000.

**Claim 73. (Withdrawn)** The method of claim 65, characterized in that the active compound inhibits at least one Sgk, in particular Sgk1 and/or Sgk3, and/or PKB, and/or stimulates at least one Nedd, in particular Nedd4-2, in particular for the purpose of preventing or treating diseases which are connected with disturbed glucose absorption.

**Claim 74. (Withdrawn)** The method of claim 65, characterized in that the active compound is at least one kinase inhibitor, preferably staurosporine and/or chelerythrine, or one of their analogs, and/or at least one ligase activator.

**Claim 75. (Withdrawn)** A method for treating diseases which are connected with disturbed glucose transport in which at least one active compound for exerting an effect on, in particular inhibiting, at least one Sgk and/or PKB, and/or for exerting an effect on, in particular stimulating, at least one Nedd, is used.

**Claim 76. (Withdrawn)** The method of claim 73, characterized in that the diseases are the metabolic syndrome, in particular obesity.

**Claim 77. (Withdrawn)** The method of claim 65, characterized in that the active compound stimulates at least one Sgk, in particular Sgk1 and/or Sgk3, and/or PKB, and/or inhibits at least one Nedd, in particular Nedd4-2, for the purpose of increasing glucose transport, in particular for increasing the bodyweight of animals.

**Claim 78. (Withdrawn)** The method of claim 77, characterized in that the active compound is at least one Sgk activator and/or PKB activator, in particular a growth factor, preferably IGF1, and/or insulin.

**Claim 79. (Withdrawn)** The method of claim 77, characterized in that the active compound is at least one stimulant of the transcription of sgk1 and/or sgk3 and/or a gene for PKB, preferably at least one glucocorticoid, mineral corticoid, gonadotropin and/or cytokine, in particular TGF $\beta$ .

**Claim 80. (Withdrawn)** A diagnostic kit which comprises at least one substance for detecting the expression and/or function of activated and/or inactive Sgk, in particular Sgk1 and/or Sgk3, and/or PKB and/or Nedd, in particular Nedd4-2, for diagnosing diseases which are associated with disturbed glucose transport.

**Claim 81. (Withdrawn)** The diagnostic kit of claim 80, characterized in that the diseases are the metabolic syndrome, in particular obesity.

**Claim 82. (Withdrawn)** An antibody, characterized in that it is directed against at least one phosphorylated kinase consensus sequence, in particular an Sgk1 consensus sequence, in a Nedd protein, in particular in the Nedd4-2 protein.

**Claim 83. (Withdrawn)** An antibody, characterized in that it is directed against at least one unphosphorylated kinase consensus sequence, in particular an Sgk1 consensus sequence, in a Nedd protein, in particular in the Nedd4-2 protein.

**Claim 84. (Withdrawn)** An antibody, characterized in that it is directed against at least one mutated kinase consensus sequence, in particular an Sgk1 consensus sequence, in a Nedd protein, in particular in the Nedd4-2 protein.

**Claim 85. (Withdrawn)** The antibody of claim 84, characterized in that the Nedd protein with a mutated kinase consensus sequence is S338DNedd4-2 and/or S444DNedd4-2.

**Claim 86. (Withdrawn)** A composition, in particular a pharmaceutical composition, comprising an effective quantity of at least one active compound which exerts an effect on glucose transport, in particular intestinal and/or renal glucose transport, and, where appropriate, a pharmaceutically acceptable excipient.

**Claim 87. (Withdrawn)** The composition of claim 86, characterized in that the active compound exerts an effect on at least one Sgk and/or PKB and/or at least one Nedd.

**Claim 88. (Withdrawn)** The composition of claim 86, characterized in that the active compound exerts an effect on activators, inhibitors, regulators and/or biological precursors of an Sgk, in particular of Sgk1 and/or Sgk3, and/or PKB and/or a Nedd, in particular Nedd4-2.

**Claim 89. (Withdrawn)** The composition of claim 86, characterized in that the active compound is a polynucleotide which preferably encodes a peptide, in particular a polypeptide.

**Claim 90. (Withdrawn)** The composition of claim 86, characterized in that the active compound is a peptide, preferably a polypeptide.

**Claim 91. (Withdrawn)** The composition of claim 90, characterized in that the peptide exerts an effect on the expression and/or function of an Sgk, in particular Sgk1 and/or Sgk3, and/or PKB and/or a Nedd, in particular Nedd4-2.

**Claim 92. (Withdrawn)** The composition of claim 86, characterized in that the active compound is a “small molecular compound”, preferably a “small molecular compound” having a molecular weight (MW) of < 1000.

**Claim 93. (Withdrawn)** The composition of claim 86, characterized in that the active compound inhibits at least one Sgk and/or PKB and/or stimulates at least one Nedd.

**Claim 94. (Withdrawn)** The composition of claim 86, characterized in that the active compound is at least one kinase inhibitor, preferably staurosporine and/or chelerythrine or one of their analogs, and/or at least one ligase activator.

**Claim 95. (Withdrawn)** The composition of claim 86, characterized in that the active compound stimulates at least one Sgk and/or PKB and/or inhibits at least one Nedd.

**Claim 96. (Withdrawn)** The composition of claim 95, characterized in that the active compound is at least one Sgk activator and/or PKB activator, in particular a growth factor, preferably IGF1, and/or insulin.

**Claim 97. (Withdrawn)** The composition of claim 95, characterized in that the active compound is at least one stimulant of the transcription of sgk1 and/or sgk3 and/or a gene for PKB, preferably at least one glucocorticoid, mineral corticoid, gonadotropin and/or cytokine, in particular TGF $\beta$ .

**Claim 98. (Withdrawn)** A method for producing transgenic animals, excluding humans, which exhibit an increase in lipid deposition in adipose tissue, characterized in that the expression and/or function of Sglt, in particular Sglt1, is increased.

**Claim 99. (Withdrawn)** The method of claim 98, characterized in that Sglt, in particular Sglt1, is overexpressed.

**Claim 100. (Withdrawn)** The method of claim 98, characterized in that the expression and/or function of at least one Sgk, in particular Sgk1 and/or Sgk3, and/or PKB, is increased.

**Claim 101. (Withdrawn)** The method of in claim 100, characterized in that at least one sgk, in particular sgk1 and/or sgk3, and/or at least one gene for PKB, is overexpressed.

**Claim 102. (Withdrawn)** The method of claim 100, characterized in that use is made of at least one activating mutation of sgk, in particular of sgk1 and/or sgk3, and/or of a gene for PKB, in particular S422Dsgk1 and/or T308D,S473DPKB.

**Claim 103. (Withdrawn)** The method of claim 98, characterized in that the expression and/or function of at least one Nedd, in particular Nedd4-2, is decreased.

**Claim 104. (Withdrawn)** The method of in claim 103, characterized in that use is made of at least one inactivating mutation of nedd, in particular of nedd4-2, in particular S338Dnedd4-2 and/or S444Dnedd4-2.

**Claim 105. (New)** The method of claim 53, wherein the antibody is a monoclonal or a polyclonal antibody.

**Claim 106. (New)** The method of claim 53, wherein the antibody is a monoclonal antibody.

**Claim 107. (New)** The method of claim 62 comprising detecting said polymorphism with an oligonucleotide directed thereto.

**Claim 108. (New)** The method of claim 53, comprising employing enzyme-linked immunosorbent assay (ELISA).